Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 234 results for "Multiple Myeloma (MM)".

Thumbnail for Beyond a Single Entity: Site-Specific Heterogeneity in Clinical Characteristics, Treatment Patterns, and Survival Outcomes Among Patients With Plasmacytoma

MM - 1315

Beyond a Single Entity: Site-Specific Heterogeneity in Clinical Characteristics, Treatment Patterns, and Survival Outcomes Among Patients With Plasmacytoma

Simo Du

Poster Presenter: Simo Du

Thumbnail for Clinical Landscape and Prognostic Impact of Extramedullary Disease in Multiple Myeloma: A Large Single-Center Retrospective Analysis

MM - 1322

Clinical Landscape and Prognostic Impact of Extramedullary Disease in Multiple Myeloma: A Large Single-Center Retrospective Analysis

Rahal Amira

Poster Presenter: Rahal Amira

Previous 1...4 5 6 7 8 9 10...26 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With First-Line Carfilzomib Versus Bortezomib in Adults With Multiple Myeloma: A Real-World Propensity-Matched Analysis

MM - 1329

Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With First-Line Carfilzomib Versus Bortezomib in Adults With Multiple Myeloma: A Real-World Propensity-Matched Analysis

Chanchal Maheshwari

Poster Presenter: Chanchal Maheshwari

$Thumbnail for Prophylactic Tocilizumab To Reduce the Risk of CRS and ICANS in Patients With Relapsed/Refractory Multiple Myeloma Treated With Elranatamab$

MM - 1330

Prophylactic Tocilizumab To Reduce the Risk of CRS and ICANS in Patients With Relapsed/Refractory Multiple Myeloma Treated With Elranatamab

Corbin Wright

Poster Presenter: Corbin Wright

Thumbnail for Multiple Myeloma Management in North Africa: Real-World Evidence and Outcomes From a 140 Patient Tunisian Cohort

MM - 1334

Multiple Myeloma Management in North Africa: Real-World Evidence and Outcomes From a 140 Patient Tunisian Cohort

Rahal Amira

Poster Presenter: Rahal Amira

$Thumbnail for Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis$

MM - 134

Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

Thumbnail for A Quarter century of Multiple Myeloma Mortality: Evolving Trends in Older Americans from a Nationwide CDC WONDER Analysis

MM - 1347

A Quarter century of Multiple Myeloma Mortality: Evolving Trends in Older Americans from a Nationwide CDC WONDER Analysis

Moazzam Hussain

Poster Presenter: Moazzam Hussain

Thumbnail for GLP-1 Receptor Agonists and Organ Function Outcomes in Amyloid Light-Chain Amyloidosis: A Real-World Analysis From the TriNetX Global Collaborative Network

MM - 1350

GLP-1 Receptor Agonists and Organ Function Outcomes in Amyloid Light-Chain Amyloidosis: A Real-World Analysis From the TriNetX Global Collaborative Network

Dhriti Sood

Poster Presenter: Dhriti Sood

$Thumbnail for Comparative Real-World Outcomes of CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Propensity-Matched TriNetX Analysis$

MM - 1370

Comparative Real-World Outcomes of CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Propensity-Matched TriNetX Analysis

Rukash Khan Niazi

Poster Presenter: Rukash Khan Niazi

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors